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ABSTRACT
Photoactivated chemotherapy (PACT) offers a targeted approach to cancer treatment through
selective drug activation. Substitutionally labile ruthenium-based prodrugs undergo ligand-loss
when irradiated, producing an unbound ligand and a Ru-aqua complex. We report the synthesis
and cytotoxicity of several new ruthenium-centered complexes and their irradiation products for
use in PACT. A series of complexes were synthesized in order to study the effects of structural
differences on cell viability. Cell viability was tested on T47D human breast cancer cells in the
presence of compound to determine cytotoxicity and dose-response. While neither the Rucomplexes nor their ligands demonstrated cytotoxicity, their Ru-aqua dissociation complexes all
demonstrated cytotoxic effects at increasing concentrations. The results indicate the potential for
the synthesized Ru-complexes to be used in PACT.

INTRODUCTION
Cancer is the second leading cause of death globally, accounting for one in six deaths. The
World Health Organization’s International Agency for Research on Cancer reported over 9.6
million cancer-related deaths and 18 million new cases of cancer in 2018, and those numbers are
expected to increase in coming years.i Traditionally, cancer patients have been treated with
surgery, chemotherapy, and radiation. Modern surgery can be minimally invasive and performed
without damage to surrounding tissues, but its use depends on tumor location and the disease
progression, as well as the relative health of the patient. Chemotherapy and radiation have also
been found to be successful for different types of cancer, but both are nonspecific and can
consequently cause severe and sometimes fatal side effects through interactions with healthy
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cells.ii Contemporary treatments such as hormone-based therapy, gene therapy, stem cell therapy,
and immunotherapy are promising for certain disease indications and progression states, but are
relatively new fields of exploration and have not yet been proven successful across a wide range
of cancer types.iii There is a clear need for additional cancer treatments that are selective for
cancer cells.
Photoactivated chemotherapy (PACT), a term first utilized by Sadler et al. in 2009, describes a
selective approach to treating cancer through the activation of a prodrug using
photoirradiation.iv,v Most PACT molecules involve a transition metal complex that is activated by
the photo-induced dissociation of a coordinated ligand, acting as a protecting group.vi Upon the
cleavage of a ligand from a PACT molecule through irradiation, one or both photoproducts may
exhibit cytotoxicity, generally through interactions with DNA or proteins, to induce cell
apoptosis, autophagy, or necrosis.vii,viii Due to the targeted nature of light irradiation, PACT offers
a more selective approach to cancer treatment and a promising avenue for exploration within
bioinorganic anticancer therapeutics.
PACT is often compared to photodynamic therapy (PDT), a similar anticancer approach utilizing
photoirradiation to create radical oxygen species through excited-state electron transfer, leading
to cell death due to oxidative stress.ix But while PDT has progressed further along the
development pipeline and has even been approved for clinical use for certain disease indications,
it relies upon the presence of oxygen, which makes it ineffective in treating hypoxic tumors. It
has also been known to cause a strong immune response.x PACT research can build upon the
knowledge gained from the developmental achievements of PDT, including the application of
fiber-optic technology for delivering light to tumors, while offering a wider range of possible
uses, especially within oncology.xi
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Much of the literature concerning PACT involves the study of ruthenium metal complexes due to
their unique optical properties, tunable properties such excitation wavelength and kinetics of
ligand dissociation, and minimal toxicity compared to other metals.xii,xiii,xiv,xv Recently, ruthenium
polypyridyl complexes have entered clinical development for cancer treatment, though none
have progressed to the point of regulatory approval.xvi Additionally, while many ruthenium
complexes have been investigated for use as PACT agents, none have advanced to clinical trials.
For many of the ruthenium PACT agents reported in the literature, it is unclear whether the
anticancer agent is the ruthenium photodissociation product or the dissociated ligand.xvii Detailed
elucidation of the mechanisms of cellular uptake and cytotoxicity for ruthenium PACT
molecules is needed to better understand the potential for these molecules to demonstrate safety
and efficacy in a clinical setting.xviii Optimization of the wavelength of activation and
photodynamic window of ruthenium PACT molecules also remain a challenge; the proper
wavelength for penetration can be tissue-specific, adding to the challenge of therapeutic
design.xix The systematic study of new ruthenium PACT molecules could provide greater
clarification about the chemical properties necessary for anticancer activity and related
mechanisms. Here, we present the synthesis, characterization, and cytotoxic activity of three
novel ruthenium PACT complexes (Figure 1) and their irradiation products (Figure 2). The
cytotoxic activity of the irradiation products was tested separately to evaluate whether the
cytotoxic effects might originate from the ruthenium photodissociation product or the dissociated
ligand. The complexes were designed using bipyridine-derived ligands with different functional
groups to provide a better understanding of effects of these chemical differences on cytotoxicity
(Figure 3).
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Figure 1. Chemical structures of ruthenium complexes [Ru-1], [Ru-2], and [Ru-3].

Figure 2. Chemical structures of ruthenium-aqua complexes [Ru-4], [Ru-5], and [Ru-6].

Figure 3. Chemical structures of ligands L1 (bpy), L2 (bpy-Me2), and L3 (bpy-(COOMe)2).

6

EXPERIMENTAL SECTION
Materials and Methods. 2,2’-Bipyridine (bpy), 2,2’-Bipyridine-4,4’-dicarboxylic acid, and 1Methylbenzimidazole were purchased from Combi-Blocks. 2,2’-bi-4-picoline (bpy-Me2) and
benzimidazole were purchased from Oakwood. Silver nitrate was purchased from Alfa-Aesar.
Magnesium sulfate was purchased from Sigma-Aldrich. All were used as received. RuL2Cl2
complexes were prepared as described in the literature.xx All other reagents were ACS grade and
used without additional purification. Microwave reactions were carried out in a CEM Discover
SP microwave synthesizer. 1H spectra were recorded on a Bruker 500 MHz spectrometer or a
Bruker 300 MHz spectrometer.
General Synthesis of [RuL3]2+ Complexes. In a typical procedure, RuL2Cl2 (300 mg, 0.619
mmol) and L (0.619 mmol) were added to a microwave vessel along with 1:1 EtOH/H2O (20
mL). The reaction was heated at 150 °C for 20 min. The resulting solution was then filtered and
the solvent was removed from the filtrate on a rotary evaporator. The solid residue was collected
and washed with Et2O. The PF6− salts of the complexes were obtained via salt metathesis where
an aqueous solution of NH4PF6 was added to a solution of the chloride salt in H2O. Orange
precipitates formed in all cases, which were filtered and washed with Et2O.
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Scheme 1. General synthesis of [RuL3]2+ complexes.
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[Ru-1]. 1H NMR (300 MHz, DMSO-d6) δ 15.66 (s, 1H), 8.86 (t, J = 7.5 Hz, 3H), 8.78 (d, J = 7.5
Hz, 1H), 8.270 – 8.062 (m, 5H), 7.95 (d, J = 5.7 Hz, 1H), 7.855 – 7.703 (m, 4H), 7.616 – 7.471
(m, 4H), 7.38 (t, J = 7.2 Hz, 1H), 7.04 (t, J = 7.2 Hz, 1H), 5.68 (d, J = 8.4 Hz, 1H).
[Ru-2]. 1H NMR (500 MHz, DMSO-d6) δ 8.71(m, 6H), 7.53 (m, 6H), 7.33 (m, 6H).
[Ru-3]. 1H NMR (500 MHz, DMSO-d6) δ 9.41 (s, 6H), 7.99 (s, 6H), 7.86 (s, 6H), 3.97 (s, 18H),
2.50 (s, 18H).
General Synthesis of [RuL2(OH2)2]2+ Complexes. In a typical procedure, RuL2Cl2 (0.619
mmol) and 210 mg AgNO3 (1.24 mmol) were added to a flask along with 1:1 MeOH/H2O (20
mL). The reaction was heated at 40 °C for 60 min. The resulting solution was then filtered
through celite and the solvent was removed from the filtrate on a rotary evaporator. The solid
residue was collected and washed with Et2O.

Scheme 2. General synthesis of [RuL2(OH2)2]2+ complexes.
[Ru-5]. 1H NMR (500 MHz, Methanol-d4) δ 9.21 (d, J = 5.8 Hz, 2H), 8.63 (s, 2H), 8.42 (s, 2H),
7.81 (m, 2H), 7.47 (d, J = 5.9 Hz, 2H), 7.08 (d, J = 6.4 Hz, 2H), 2.78 (d, J = 18.4 Hz, 6H), 2.49
(d, J = 13.9 Hz, 6H).
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[Ru-6]. 1H NMR (500 MHz, Methanol-d4) δ 9.54 (d, J = 20.0 Hz, 2H), 9.24 (d, J = 56.0 Hz, 2H),
9.01 (d, J = 69.0 Hz, 2H), 8.43 (d, J = 85.3 Hz, 2H), 8.02 (d, J = 30.5 Hz, 2H), 7.67 (d, J = 32.6
Hz, 2H), 4.15 (m, 6H), 4.02 (m, 6H).
Synthesis of L3. 2,2’-Bipyridine-4,4’-dicarboxylic acid (1.00 g, 4.0 mmol) was added to a flask
along with 18 mL MeOH and 2 mL H2SO4. The reaction was heated at 75 °C overnight. The
product was extracted in 50 mL dichloromethane with three rinses of H2O, dried with
magnesium sulfate, and isolated by removal of the solvent on a rotary evaporator. Yield: 76.5%.
Cell Viability. The cytotoxic effects of the compounds on T47D human breast cancer cells was
measured using the CellTiter-Blue® Cell Viability Assay.xxi T47D cells were cultured in RPMI1640 media with L-glutamine (GenClone) supplemented with 10% heat-inactivated fetal bovine
serum (Invitrogen) and 100 U/mL Penicillin-100 μg/mL Streptomycin (GenClone) at 37°C and
5% CO2. For each experiment, the cells were seeded into a 96-well plate with 5,000 cells/well
(100 μL/well) and grown for 2-4 days. Then the cells were washed with PBS. Indicated
concentrations of compound were added to the wells in triplicate. After 24 hours of incubation at
37°C, the cells were incubated for 2 hours in the presence of 0.15 mg/mL resazurin in PBS (pH
7.4). Fluorescence was measured using an excitation wavelength of 555 nm and an emission
wavelength of 585 nm using a SpectroMax i3 plate reader (Molecular Devices).

RESULTS AND DISCUSSION
For a compound to be suitable for PACT, it should not be cytotoxic until activated by light
irradiation. This allows for clinical treatment to be selective for cancer cells, as light irradiation
can be targeted in patients to activate a prodrug in only specific tumors and tissues. In this study,
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each series of synthesized complexes could be considered suitable for PACT if the [RuL3]2+
complex was biologically inactive and at least one of the irradiation products was found to be
cytotoxic. It is hypothesized that upon irradiation, a ligand dissociates from the [RuL3]2+
complex, and water molecules from the surrounding environment coordinate to the ruthenium
metal center in its place (Scheme 3). Ruthenium complexes [Ru-4], [Ru-5], and [Ru-6] were
synthesized to mimic the likely irradiation products of [Ru-1], [Ru-2], and [Ru-3], respectively.
All synthesized compounds were characterized using 1H NMR spectroscopy. Their cytotoxic
effects on T47D cells were then evaluated to determine whether [Ru-1], [Ru-2], and [Ru-3] have
potential for use in photoactivated chemotherapy. The cytotoxicity of the ruthenium irradiation
products and individual ligands were tested separately, since it is important to know where the
toxicity originates when considering a molecule for PACT.
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Scheme 3. General scheme for light-activated ligand dissociation from [RuL3]2+ complexes.
None of the [RuL3]2+ complexes demonstrated cytotoxicity, as cell survival, measured in
fluorescence, did not decrease in the presence of increasing concentrations of these compounds
(Figure 4). Since these complexes were designed to be used as prodrugs, these preliminary
results confirm the possibility that any of these three compounds could be suitable for PACT,
given that one of their irradiation products proves to be cytotoxic.
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Figure 4. Cytotoxicity dose responses of [RuL3]2+ complexes in T47D cells. (A) [Ru-1];
(B) [Ru-2]; (C) [Ru-3]. n = 3.
Excitingly, all three of the [Ru(L2)(OH2)2]2+ complexes displayed strong cytotoxic activity, with
significant cell death occurring in the presence of higher concentrations of these complexes
(Figure 5). The EC50 values calculated for each of these complexes are shown in Table 1. Since
the [RuL3]2+ complexes did not demonstrate cytotoxicity but the [Ru(L2)(OH2)2]2+ did, these
results exhibit promising potential for [Ru-1], [Ru-2], and [Ru-3] to be used as PACT prodrugs.
While each of the [Ru(L2)(OH2)2]2+ complexes clearly show a trend toward cytotoxicity, more
studies of compounds [Ru-4] and [Ru-6] are needed to demonstrate their ability to cause
complete cell death at high concentrations, as seen with [Ru-5] (Figure 5B).

Figure 5. Cytotoxicity dose responses of [RuL2(OH2)2]2+ complexes in T47D cells. (A) [Ru-4];
(B) [Ru-5]; (C) [Ru-6]. n = 3.
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95%
Standard
Confidence
Error
Interval

95%
Confidence
EC50 (nM)
Interval
(CI)

Compound

log(EC50)
(nM)

[Ru-4]

2.14

0.1761

(1.765 2.611)

138

(56.98 408.2)

0.8836

21

[Ru-5]

2.785

0.04657

(2.6892.884)

609.6

(488.6 765.4)

0.9847

33

[Ru-6]

2.812

0.183

(2.518 –
3.338)

659.1

(329.8 2179)

0.9524

27

R2

Degrees
of freedom

Table 1. The cytotoxicity EC50 values of [Ru-4], [Ru-5], and [Ru-6] in T47D cells. Data were
collected using a CellTiter-Blue® Cell Viability Assay and analyzed using least-squares
regression. EC50 values are averages from assays run in triplicate.
Similar to the [RuL3]2+ complexes, none of the ligands themselves demonstrated cytotoxicity at
the concentrations tested (Figure 6). Based on these results, it is likely that if the [RuL3]2+
complexes were to be photoactivated, the resulting cytotoxicity would come from the ruthenium
photoproduct and not from the dissociated ligand, since the ligands showed no cytotoxicity on
their own. The cytotoxicity of the ligands was generally more variable than that of the ruthenium
complexes, possibly due to issues with solubility. Though each of the complexes and ligands
tested were dissolved in ethanol prior to adding them to the cell media for cell treatment, L1 was
dissolved in DMSO because of increased solubility compared to ethanol.
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Figure 6. Cytotoxicity dose responses of ligands in T47D cells. (A) L1; (B) L2; (C) L3. n = 3.
T47D cells were chosen as an appropriate cellular model for testing the cytotoxicity of these
compounds because of the potential for PACT to be used to treat triple-negative and multidrugresistant breast cancer and because methods of light delivery to breast tissue have already been
established.xxii,xxiii Further studies in other cell lines, such as A549 human lung carcinoma cells,
should be conducted to confirm the results found in the T47D cells and evaluate the possibility of
using these compounds to treat other cancer types.
In drug design, EC50 values are often used to determine the potency of a given compound. They
represent the concentration of compound needed to cause half of the maximal biological
response. For a lead small molecule compound in a drug discovery pipeline, it is generally
agreed that compounds with EC50 values below 1 μM are good candidates for further
optimization.xxiv A comparison of the EC50 values calculated for [Ru-4], [Ru-5], and [Ru-6]
reveals that [Ru-4] is significantly more potent than [Ru-5], with EC50 values of 138 nM (56.98408.2) and 609.6 nM (448.6-765.4), respectively. The EC50 value of [Ru-6] is the highest at
659.1 nM (329.8-2179), but the error is too large to determine whether this is significantly higher
than either of the other two complexes. The fact that these compounds have EC50 values in the
nM range indicates they are effective drug candidates. From these data, it seems that the
complexes become less potent with increasing ligand size, although additional studies must be
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done to confirm this trend and it may instead be due to other factors, such as electronic properties
that vary significantly across the series. It is possible that the electron-donating character of the
methyl groups on L2 and the electron-withdrawing character of the carboxymethyl groups on L3
affected the potency of [Ru-5] and [Ru-6], but further investigation is necessary to explore these
trends.
Along with potency, ease of ligand dissociation is another important factor in determining
whether a compound might make an effective PACT prodrug. While [Ru-4] might have been the
most potent of the three ruthenium photoproducts synthesized, this does not necessarily mean
[Ru-1] is the best candidate for further investigation, as it could prove to be more difficult to
photoactivate than [Ru-2] or [Ru-3]. The wavelength at which ligand dissociation occurs is also
an essential factor in determining whether a compound can be used to treat tumors in different
tissue areas, as different tissues absorb different wavelengths of light. The chemical differences
between the ligands on the complexes studied might cause them to dissociate at different
wavelengths and be optimal for treatment of different cancer types. The photoactivation of the
[RuL3]2+ compounds studied here is yet to be explored.
One idea for increasing the ease of ligand photodissociation from ruthenium PACT complexes is
to design complexes with monodentate ligands rather than bidentate ligands. Designing
complexes with cytotoxic ligands is also an important strategy in optimizing the potency of the
photoactivated compounds. Combining these two properties, there are examples in the literature
of

cytotoxic

ruthenium

complexes

containing

monodentate

benzimidazole-derived

ligands.xxv,xxvi,xxvii For this reason, we studied the cytotoxicity of two monodentate ligands,
benzimidazole and 1-methylbenzimidazole (Figure 7). Though neither of these compounds
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demonstrated cytotoxicity (Figure 8), this avenue of inquiry may be worth pursuing. We have not
yet proceeded with coordinating these ligands to ruthenium complexes.

HN

N

Benzimidazole

H 3C

N

N

1-Methylbenzimidazole

Figure 7. Chemical structures of benzimidazole and 1-methylbenzimidazole.

Figure 8. Cytotoxicity dose responses of ligands in T47D cells. (A) Benzimidazole;
(B) 1-methylbenzimidazole. n = 3.

CONCLUSIONS
In conclusion, we have demonstrated the cytotoxic properties of three novel ruthenium
complexes and their ligand dissociation products. While the ruthenium complexes and their
ligands exhibited no effect on cell viability, their Ru-aqua dissociation complexes were
demonstrated to be cytotoxic at increasing concentrations. The potency of these complexes were
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investigated and compared. The findings of this study demonstrate the potential use of [Ru-1],
[Ru-2], and [Ru-3] as PACT compounds.
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